Recurrent and novel SS18-SSX fusion transcripts in synovial sarcoma: description of three new cases

详细信息    查看全文

• 作者：Joanna Przybyl (1) (4) (6)
  Raf Sciot (2)
  Piotr Rutkowski (3)
  Janusz A. Siedlecki (1)
  Vanessa Vanspauwen (4)
  Ignace Samson (5)
  Maria Debiec-Rychter (4)
  
• 关键词：Synovial sarcoma ; Molecular markers ; Fusion genes ; SS18 ; SSX fusion genes
• 刊名：Tumor Biology
• 出版年：2012
• 出版时间：December 2012
• 年：2012
• 卷：33
• 期：6
• 页码：2245-2253
• 全文大小：747KB
• 参考文献：1. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytogenet. 2003;143(1):1-1. CrossRef
  2. Limon J, Dal Cin P, Sandberg AA. Translocations involving the X chromosome in solid tumors: presentation of two sarcomas with t(X;18)(q13;p11). Cancer Genet Cytogenet. 1986;23(1):87-1. CrossRef
  3. Turc-Carel C, Dal Cin P, Limon J, Li F, Sandberg AA. Translocation X;18 in synovial sarcoma. Cancer Genet Cytogenet. 1986;23(1):93. CrossRef
  4. Panagopoulos I, Mertens F, Isaksson M, Limon J, Gustafson P, Skytting B, et al. Clinical impact of molecular and cytogenetic findings in synovial sarcoma. Genes Chromosomes Cancer. 2001;31(4):362-2. CrossRef
  5. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res. 2002;62(1):135-0.
  6. Mitelman F, Johansson B, Mertens F (eds) (2011) Mitelman database of chromosome aberrations in cancer. Available at: http://cgap.nci.nih.gov/Chromosomes/Mitelman. Accessed on March 7, 2011.
  7. Crew AJ, Clark J, Fisher C, Gill S, Grimer R, Chand A, et al. Fusion of SYT to two genes, SSX1 and SSX2, encoding proteins with homology to the Kruppel-associated box in human synovial sarcoma. EMBO J. 1995;14(10):2333-0.
  8. Kawai A, Woodruff J, Healey JH, Brennan MF, Antonescu CR, Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med. 1998;338(3):153-0. CrossRef
  9. Guillou L, Benhattar J, Bonichon F, Gallagher G, Terrier P, Stauffer E, et al. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol. 2004;22(20):4040-0. CrossRef
  10. Skytting B, Nilsson G, Brodin B, Xie Y, Lundeberg J, Uhlén M, et al. A novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 1999;91(11):974-. CrossRef
  11. Agus V, Tamborini E, Mezzelani A, Pierotti MA, Pilotti S. Re: a novel fusion gene, SYT-SSX4, in synovial sarcoma. J Natl Cancer Inst. 2001;93(17):1347-. CrossRef
  12. Brodin B, Haslam K, Yang K, Bartolazzi A, Xie Y, Starborg M, et al. Cloning and characterization of spliced fusion transcript variants of synovial sarcoma: SYT/SSX4, SYT/SSX4v, and SYT/SSX2v. Possible regulatory role of the fusion gene product in wild type SYT expression. Gene. 2001;268(1-):173-2. CrossRef
  13. Amary MF, Diss TC, Flanagan AM. Molecular characterization of a novel variant of a SYT-SSX1 fusion transcript in synovial sarcoma. Histopathology. 2007;51(4):559-1. CrossRef
  14. Nilsson G, Skytting B, Xie Y, Brodin B, Perfekt R, Mandahl N, et al. The SYT-SSX1 variant of synovial sarcoma is associated with a high rate of tumor cell proliferation and poor clinical outcome. Cancer Res. 1999;59(13):3180-.
  15. Inagaki H, Nagasaka T, Otsuka T, Sugiura E, Nakashima N, Eimoto T. Association of SYT-SSX fusion types with proliferative activity and prognosis in synovial sarcoma. Mod Pathol. 2000;13(5):482-. CrossRef
  16. Sun Y, Sun B, Wang J, Cai W, Zhao X, Zhang S, et al. Prognostic implication of SYT-SSX fusion type and clinicopathological parameters for tumor-related death, recurrence, and metastasis in synovial sarcoma. Cancer Sci. 2009;100(6):1018-5. CrossRef
  17. Wei X, Sun Y, Zhao X, Cai W, Xia W, Lou D, et al. The influence of SYT-SSX fusion gene, E-cadherin and β-catenin on the metastasis of synovial sarcoma. Chin J Clin Oncol. 2010;37(4):205-.
  18. Ladanyi M. Correlates of SYT-SSX fusion type in synovial sarcoma: getting more complex but also more interesting? J Clin Oncol. 2005;23(15):3638-. author reply 3639-40. CrossRef
  19. Takenaka S, Ueda T, Naka N, Araki N, Hashimoto N, Myoui A, et al. Prognostic implication of SYT-SSX fusion type in synovial sarcoma: a multi-institutional retrospective analysis in Japan. Oncol Rep. 2008;19(2):467-6.
  20. Pelosi G. The Arkadi M. Rywlin International Pathology Slide Seminar Club, Seminar #51, Case 14. Contributed by: Giuseppe Pelosi, MD, Division of Pathology and Laboratory Medicine, European Institute of Oncology and University of Milan School of Medicine, Milan, Italy. Available at: www.amr-seminar.org. Published on May 28, 2007. Accessed on February 7, 2012.
  21. Mezzelani A, Mariani L, Tamborini E, Agus V, Riva C, Lo Vullo S, et al. SYT-SSX fusion genes and prognosis in synovial sarcoma. Br J Cancer. 2001;85(10):1535-. CrossRef
  22. Surace C, Panagopoulos I, Palsson E, Rocchi M, Mandahl N, Mertens F. A novel FISH assay for SS18-SSX fusion type in synovial sarcoma. Lab Invest. 2004;84(9):1185-2. CrossRef
  23. Fligman I, Lonardo F, Jhanwar SC, Gerald WL, Woodruff J, Ladanyi M. Molecular diagnosis of synovial sarcoma and characterization of a variant SYT-SSX2 fusion transcript. Am J Pathol. 1995;147(6):1592-.
  24. Safar A, Wickert R, Nelson M, Neff JR, Bridge JA. Characterization of a variant SYT-SSX1 synovial sarcoma fusion transcript. Diagn Mol Pathol. 1998;7(5):283-. CrossRef
  25. Sanders ME, van de Rijn M, Barr FG. Detection of a variant SYT-SSX1 fusion in a case of predominantly epithelioid synovial sarcoma. Mol Diagn. 1999;4(1):65-0. CrossRef
  26. Sonobe H, Takeuchi T, Liag SB, Taguchi T, Yuri K, Shimizu K, et al. A new human synovial sarcoma cell line, HS-SY-3, with a truncated form of hybrid SYT/SSX1 gene. Int J Cancer. 1999;82(3):459-4. CrossRef
  27. O’Sullivan MJ, Humphrey PA, Dehner LP, Pfeifer JD. t(X;18) reverse transcriptase-polymerase chain reaction demonstrating a variant transcript. J Mol Diagn. 2002;4(3):178-0. CrossRef
  28. T?rnkvist M, Brodin B, Bartolazzi A, Larsson O. A novel type of SYT/SSX fusion: methodological and biological implications. Mod Pathol. 2002;15(6):679-5. CrossRef
  29. Storlazzi CT, Mertens F, Mandahl N, Gisselsson D, Isaksson M, Gustafson P, et al. A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer. 2003;37(2):195-00. CrossRef
  30. Otsuka S, Nishijo K, Nakayama T, Aoyama T, Ishibe T, Shibata KR, et al. A variant of the SYT-SSX2 fusion gene in a case of synovial sarcoma. Cancer Genet Cytogenet. 2006;167(1):82-. CrossRef
  31. Krsková L, Sumerauer D, Stejskalová E, Kodet R. A novel variant of SYT-SSX1 fusion gene in a case of spindle cell synovial sarcoma. Diagn Mol Pathol. 2007;16(3):179-3. CrossRef
  32. Dimitriadis E, Rontogianni D, Kyriazoglou A, Takou A, Frangia K, Pandis N, et al. Novel SYT-SSX fusion transcript variants in synovial sarcoma. Cancer Genet Cytogenet. 2009;195(1):54-. CrossRef
  33. Nakashima S, Morinaka K, Koyama S, Ikeda M, Kishida M, Okawa K, et al. Small G protein Ral and its downstream molecules regulate endocytosis of EGF and insulin receptors. EMBO J. 1999;18(13):3629-2. CrossRef
  34. Oosterhoff JK, Penninkhof F, Brinkmann AO, Anton Grootegoed J, Blok LJ. REPS2/POB1 is downregulated during human prostate cancer progression and inhibits growth factor signalling in prostate cancer cells. Oncogene. 2003;22(19):2920-. CrossRef
  35. Oosterhoff JK, Kühne LC, Grootegoed JA, Blok LJ. EGF signalling in prostate cancer cell lines is inhibited by a high expression level of the endocytosis protein REPS2. Int J Cancer. 2005;113(4):561-. CrossRef
  36. Tomassi L, Costantini A, Corallino S, Santonico E, Carducci M, Cesareni G, et al. The central proline rich region of POB1/REPS2 plays a regulatory role in epidermal growth factor receptor endocytosis by binding to 14-3-3 and SH3 domain-containing proteins. BMC Biochem. 2008;9:21. CrossRef
  37. Penninkhof F, Grootegoed JA, Blok LJ. Identification of REPS2 as a putative modulator of NF-kappaB activity in prostate cancer cells. Oncogene. 2004;23(33):5607-5. CrossRef
  38. Doolan P, Clynes M, Kennedy S, Mehta JP, Germano S, Ehrhardt C, et al. TMEM25, REPS2 and Meis 1: favourable prognostic and predictive biomarkers for breast cancer. Tumour Biol. 2009;30(4):200-. CrossRef
  39. Badway JA, Baleja JD. Reps2: a cellular signaling and molecular trafficking nexus. Int J Biochem Cell Biol. 2011;43(12):1660-. CrossRef
  
• 作者单位：Joanna Przybyl (1) (4) (6)
  Raf Sciot (2)
  Piotr Rutkowski (3)
  Janusz A. Siedlecki (1)
  Vanessa Vanspauwen (4)
  Ignace Samson (5)
  Maria Debiec-Rychter (4)
  
  1. Department of Molecular Biology, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, 5 W.K. Roentgen Street, 02-781, Warsaw, Poland
  4. Department of Human Genetics, K.U. Leuven and University Hospitals, Leuven, Belgium
  6. Postgraduate School of Molecular Medicine, Warsaw Medical University, Warsaw, Poland
  2. Department of Pathology, K.U. Leuven and University Hospitals, Leuven, Belgium
  3. Department of Soft Tissue/Bone Sarcoma and Melanoma, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland
  5. Department of Orthopedic Surgery, University Hospitals, Leuven, Belgium
  
• ISSN：1423-0380

文摘

Synovial sarcoma (SS) is an aggressive type of tumor, comprising approximately 10?% of soft tissue sarcomas. Over 90?% of SS cases are characterized by the t(X;18)(p11.2;q11.2) translocation, which results mainly in the formation of oncogenic SS18-SSX1 or SS18-SSX2 fusions. In a typical SS18-SSX fusion transcript, exon 10 of SS18 is fused to exon 6 of SSX1/2. However, several variant fusion transcripts have been already described. In the present study, we examined the fusion transcript type in a series of 40 primary untreated SS tumor specimens using reverse transcription polymerase chain reaction and fluorescence in situ hybridization assay. We detected SS18-SSX1 transcript in 22 (55?%) patients and SS18-SSX2 transcript in 17 (42.5?%) patients, while in one patient, none of SS18-SSX1/2 fusion transcripts were identified. Among the cases under study, two tumors carried novel SS18-SSX1 and SS18-SSX2 variant translocations that were allegedly created by an alternative splicing, and in additional case, an unusual translocation variant previously described by other group was found. Our data suggest that alternative splicing may play an important role in novel fusion transcript formation, and additionally we show that it may be a recurrent event in SS. Furthermore, we describe the first case of a complex rearrangement possibly linking SS to REPS2 gene.